Molecular Markers in Treatment in Endometrial Cancer
- Conditions
- Endometrial NeoplasmsNeoplasm Metastasis
- Registration Number
- NCT00598845
- Lead Sponsor
- University of Bergen
- Brief Summary
The purpose of this prospective multicenter trial is to investigate the value of molecular markers in endometrial cancer for predicting lymph node metastasis and prognosis in relation to treatment.
- Detailed Description
This is a prospective multicenter study to investigate the predictive value of molecular markers in endometrial cancer for lymph node metastasis, prognosis and treatment. For the previously studied tumor markers p53, p16, ER, PR and HER2neu, we want to investigate the expression in curettage material in relation to lymph node metastasis and prognosis among endometrial carcinoma patients. We also want to investigate the distribution of genetic alterations in fresh frozen tumor tissue in order to design prospective randomized treatment trials of metastatic endometrial cancer based on molecular profile. There will be a special emphasis on disturbances in the pathways influenced by new targeted therapy, such as inhibitors of Her2/NEU, EGFR, receptor tyrosine kinase, mTOR, PTEN and hormone receptor pathways.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 1000
- Women with endometrial carcinoma
- Available endometrial biopsy
- Informed consent
- No informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Presence of lymph node metastases At primary treatment
- Secondary Outcome Measures
Name Time Method Recurrent disease, death from disease 5 years after primary treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (9)
Gynecological Oncology, UZ Gasthuisberg
🇧🇪Leuven, Belgium
Sentralsykehuset i Førde
🇳🇴Førde, Norway
Helse-Fonna, Haugesund Sjukehus
🇳🇴Haugesund, Norway
Kvinneklinikken, Akershus Universitetssykehus
🇳🇴Lørenskog, Norway
Kvinnesenteret, Ullevål Universitetssykehus
🇳🇴Oslo, Norway
Department of Gynecology, St Olav's Hospital
🇳🇴Trondheim, Norway
Sykehuset Vestfold HF
🇳🇴Tønsberg, Norway
Department of Gynecology, Ålesund Hospital
🇳🇴Ålesund, Norway
Senter for Surgical Gynecologic Oncology, Sahlgrenska University Hospital
🇸🇪Gothenburg, Sweden
Gynecological Oncology, UZ Gasthuisberg🇧🇪Leuven, BelgiumFrederic Amant, MD, PhDContactFrederic.amant@uz.kuleuven.ac.be